ZA201803875B - Interleukin-15 compositions and uses thereof - Google Patents
Interleukin-15 compositions and uses thereofInfo
- Publication number
- ZA201803875B ZA201803875B ZA2018/03875A ZA201803875A ZA201803875B ZA 201803875 B ZA201803875 B ZA 201803875B ZA 2018/03875 A ZA2018/03875 A ZA 2018/03875A ZA 201803875 A ZA201803875 A ZA 201803875A ZA 201803875 B ZA201803875 B ZA 201803875B
- Authority
- ZA
- South Africa
- Prior art keywords
- interleukin
- compositions
- Prior art date
Links
- 102000003812 Interleukin-15 Human genes 0.000 title 1
- 108090000172 Interleukin-15 Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270447P | 2015-12-21 | 2015-12-21 | |
| PCT/US2016/067042 WO2017112528A2 (en) | 2015-12-21 | 2016-12-15 | Interleukin-15 compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201803875B true ZA201803875B (en) | 2019-08-28 |
Family
ID=59091160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/03875A ZA201803875B (en) | 2015-12-21 | 2018-06-11 | Interleukin-15 compositions and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180360977A1 (https=) |
| EP (1) | EP3393486A4 (https=) |
| JP (1) | JP2019503348A (https=) |
| KR (1) | KR20180089516A (https=) |
| CN (1) | CN108472324A (https=) |
| AU (1) | AU2016378387A1 (https=) |
| BR (1) | BR112018012262A2 (https=) |
| CA (1) | CA3007819A1 (https=) |
| IL (1) | IL259919A (https=) |
| MX (1) | MX2018007304A (https=) |
| WO (1) | WO2017112528A2 (https=) |
| ZA (1) | ZA201803875B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| CN112004547A (zh) | 2018-02-26 | 2020-11-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| WO2020097556A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| CN114126638A (zh) * | 2019-04-26 | 2022-03-01 | 普罗林科斯有限责任公司 | 缓慢释放的细胞因子偶联物 |
| IL288210B2 (en) | 2019-05-20 | 2026-03-01 | Cytune Pharma | Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases |
| JP2022544405A (ja) * | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| EP4017540A1 (en) * | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| EP4232068A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN118251495A (zh) * | 2021-11-26 | 2024-06-25 | 杰科（天津）生物医药有限公司 | 一种蛋白的生产方法及其应用 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN117510828A (zh) * | 2022-07-28 | 2024-02-06 | 厦门赛诺邦格生物科技股份有限公司 | 一种含氨基酸残基的三臂聚乙二醇衍生物 |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367027T3 (es) * | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| TW200613552A (en) * | 2004-08-11 | 2006-05-01 | Hoffmann La Roche | Mutant interleukin-15 polypeptides |
| JP2008515896A (ja) * | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| WO2016060996A2 (en) * | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
-
2016
- 2016-12-15 MX MX2018007304A patent/MX2018007304A/es unknown
- 2016-12-15 WO PCT/US2016/067042 patent/WO2017112528A2/en not_active Ceased
- 2016-12-15 EP EP16879902.1A patent/EP3393486A4/en not_active Withdrawn
- 2016-12-15 BR BR112018012262A patent/BR112018012262A2/pt not_active Application Discontinuation
- 2016-12-15 AU AU2016378387A patent/AU2016378387A1/en not_active Abandoned
- 2016-12-15 CA CA3007819A patent/CA3007819A1/en not_active Abandoned
- 2016-12-15 JP JP2018530797A patent/JP2019503348A/ja not_active Withdrawn
- 2016-12-15 KR KR1020187020534A patent/KR20180089516A/ko not_active Withdrawn
- 2016-12-15 CN CN201680079249.3A patent/CN108472324A/zh active Pending
- 2016-12-15 US US16/060,389 patent/US20180360977A1/en not_active Abandoned
-
2018
- 2018-06-10 IL IL259919A patent/IL259919A/en unknown
- 2018-06-11 ZA ZA2018/03875A patent/ZA201803875B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018012262A2 (pt) | 2018-12-04 |
| WO2017112528A3 (en) | 2017-08-31 |
| IL259919A (en) | 2018-07-31 |
| WO2017112528A2 (en) | 2017-06-29 |
| JP2019503348A (ja) | 2019-02-07 |
| AU2016378387A1 (en) | 2018-07-05 |
| KR20180089516A (ko) | 2018-08-08 |
| CN108472324A (zh) | 2018-08-31 |
| MX2018007304A (es) | 2019-03-14 |
| US20180360977A1 (en) | 2018-12-20 |
| EP3393486A2 (en) | 2018-10-31 |
| CA3007819A1 (en) | 2017-06-29 |
| EP3393486A4 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201803875B (en) | Interleukin-15 compositions and uses thereof | |
| ZA201702213B (en) | Interleukin-15 compositions and uses thereof | |
| GB2546350B (en) | Compositions and methods | |
| HUE065174T2 (hu) | HLA-alapú módszerek és készítmények, valamint azok felhasználása | |
| ZA201803451B (en) | Probiotic compositions and uses thereof | |
| IL250568B (en) | Anti-methanogenic preparations and their uses | |
| SG11201707876YA (en) | Microalgal compositions and uses thereof | |
| GB201519187D0 (en) | Improved binder compositions and uses thereof | |
| GB201519188D0 (en) | Improved binder compositions and uses thereof | |
| GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
| GB201706352D0 (en) | Methods compositions and uses relating thereto | |
| GB201706355D0 (en) | Methods compositions and uses relating thereto | |
| GB201502002D0 (en) | Uses and compositions | |
| GB201706356D0 (en) | Methods compositions and uses relating thereto | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| GB201715785D0 (en) | Methods compositions and uses relating thereto | |
| GB2550632B (en) | Compositions and uses and methods relating thereto | |
| GB201715820D0 (en) | Compositions and methods | |
| GB201705626D0 (en) | Compositions and methods | |
| GB201501991D0 (en) | Uses and compositions | |
| GB201502026D0 (en) | Uses and compositions | |
| ZA201807665B (en) | Methods and compositions | |
| GB201512996D0 (en) | Compositions and methods | |
| GB201614897D0 (en) | Compositions and uses thereof | |
| IL248863A0 (en) | Preparations containing il-31 and their use |